Inactive Instrument

Creative Antibiotics Sweden AB Stock

Stocks

CAS

SE0001136474

Biotechnology & Medical Research

End-of-day quote Nasdaq Stockholm
- SEK - Intraday chart for Creative Antibiotics Sweden AB
Manager TitleAgeSince
Chief Executive Officer - 2010-05-17
Corporate Officer/Principal - 2009-12-31
Corporate Officer/Principal - 2010-05-17
Change 5-day change 1-year change 3-year change Capi.($)
+4.43%+0.21%+60.07%+115.25% 52.88B
+1.58%+19.37%+75.37%+85.18% 50.98B
-0.23%-2.41%-14.36%-16.00% 22.81B
+0.98%+6.11%-1.35%+423.40% 22.43B
+2.03%+10.85%+30.31%-12.32% 17.01B
+0.88%+5.07%+28.91%-34.26% 15.91B
+0.68%+1.51%+16.43%+168.03% 13.29B
+3.02%+18.32%+141.11%+308.04% 13.58B
+0.79%+2.79%+80.29%+116.18% 11.75B
Average +1.54%+4.59%+46.31%+128.17% 24.52B
Weighted average by Cap. +1.96%+4.49%+48.56%+120.53%
Logo Creative Antibiotics Sweden AB
Creative Antibiotics Sweden AB, formerly Innate Pharmaceuticals AB, is a Sweden-based company that is active within the biotechnology industry. Its main business activity comprises the development of anti-infective agents to treat infectious diseases caused by Gram-negative bacteria. The agents disarm the pathogenic capability of certain bacteria, without affecting normal bacterial flora. The Company's activity is based on the research within innate immunity, medical chemistry and microbiology. It focuses on three projects, which involve the development of agents against severe burns, diarrhea diseases and chlamydia infections. As of December 31, 2011, the Company's three largest shareholders were Forsakringsaktiebolaget, Avanza pension (10.95%), Tuja Invest AB (6.23%) and Ostersjostiftelsen (5.67%).
Employees
-